Tag: NASDAQ: UXIN

  • UXIN stock surges in the pre-market trading session. Here’s to know why?

    UXIN stock surges in the pre-market trading session. Here’s to know why?

    UXIN stock surged by 12.5% at the last trading close while the UXIN stock price kept on rising by 17.95% in the pre-market trading session after UXIN announced that they have signed a binding term sheet with two well-established Asian funds. In China, UXIN is a leading online pre-used car dealer with a nationwide presence. UXIN’s goal is to empower people to buy the car of their dreams online by providing high-quality used cars and best-in-class shopping services. UXIN’s one-stop online shopping mall offers customers a national range of affordable used vehicles, as well as a variety of value-added goods and services.

    How does UXIN works?

    Its online sales consultants provides expert advice to help customers make a quick and easy car purchase. To complete these online transactions, its robust fulfillment program provides nationwide logistics and distribution, as well as title transfers between different cities across China.

    What is happening?

    On April 1, 2021, UXIN signed a binding term sheet with two existing Asian funds, committing the potential investors to negotiate and eventually enter into definitive agreements with the Company for the subscription of senior convertible preferred shares. The proposed transaction could result in a cumulative investment of up to $300 million. The potential transaction’s completion is dependent on the parties’ implementation of definitive agreements and the stipulation of customary closing conditions therein.

    Conclusion

    Following this new positive development in UXIN, it is expected that UXIN will be able to make visible progress in the future but under these uncertain COVID-19 situations, the definite verdict cannot be given since the working of businesses around the globe, be it of any type are subject to change due to unfortunate pandemic scenario. Besides this, investors would definitely be interested in UXIN stock because of this deal.

  • Profitable Stocks to Trade Today for  Exponential Gains

    Profitable Stocks to Trade Today for  Exponential Gains

    Aptinyx Inc [NASDAQ: APTX]

    Clinical-stage biopharmaceutical company Aptinyx Inc., reported today of its positive results from the second phase of its novel NVDA receptor module, NYX-783 clinical trial.

    The study involved 153 patients suffering from post-traumatic-stress disorder (PTSD). In this study, NYX-783 showed statistically and clinically significant efficacy results of this treatment. Following these results, Aptinyx expects to kick-start a serious study in 2021. PTSD is one of the most difficult psychiatric conditions to treat due to multiple debilitating symptoms.

    Murray Stein, the Vice-Chair for Clinical Research in Psychiatry at the University of California San Diego says that it is encouraging to get such positive results and considering the short duration that NYX-783 takes to cure this disorder.

    Uxin Ltd [NASDAQ: UXIN]

    Uxin Limited, an international online Chinese company dealing with used cars recently announced that it has entered into two definitive agreements with two investors that will see the company raise US$25,000,000.

    In these agreements, Uxin plans to issue an aggregate of 84,692,839 Class A ordinary shares through private placements that will occur in October 2020. Additionally, Uxin also entered into a letter agreement with affiliates of TPG, 58.com and Warburg Pincus to alter the conversion of price of the convertible notes in an aggregate total of about US$230 million.

    Based on this letter in two years after the agreement, if the Company issues or sells any equity securities less than the conversion price, the strategic investors will have a right to convert all or a part of their convertible notes at a price that is equal to New Issue Price.

    Iterum Therapeutics Plc  [NASDAQ: ITRM]

    Iterum Therapeutics plc announced today that it will present its data at the Infectious Disease Society of America IDWeek that will take place virtually as from October 21, 2020.

    The data presentations will include results for SURE-2, that will show the effects in complicated urinary tract infections (cUTI) and oral abstract presentation that are results from SURE-1 in uncomplicated urinary tract infections..

    This data shows that oral sulopenem was statistically stronger than oral ciprofloxacin to treat patients with uncomplicated urinary tract infections. Iterum Therapeutics is a clinical-stage pharmaceutical institution that is focussed on developing oral and IV antibiotics for the treatment and management of infections caused by drug resistant pathogens in both hospital and home settings.